Authors
1 Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Resident, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Resident, Department of Internal Medicine, School of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
4 General Practitioner, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Human T-cell lymphotropic virus HTLV-I/II is a retrovirus that has been associated with different diseases. HTLV-I/II routes of transmissions are exposure to contaminated blood, blood transfusion, needle sharing, breast feeding, and sexual contact. The seroprevalence of HTLV-I/II in HIV infected patients has not been well characterized in Iran. We conducted a serological survey to determine the relative frequency of HTLV-I/II in HIV+/AIDS and healthy blood donors in Isfahan.
Materials and Methods: In this cross-sectional study, we compare the relative frequency of HTLV-I/II in HIV+/AIDS group (56 persons) with asymptomatic blood donors (57 persons) in Isfahan. Participant completed the questionnaires that include demographic information, age, sex, and sexual partnership during last 6 months, sexual behavior and past history of blood transfusion or other blood products. We confirm the HIV+ status in patients group with western blot test. Evaluation of HTLV-I/II were done using ELISA test with DRAPIO third generation kit. Questionnaire data and laboratory results were analyzed by SPSS18.
Results: During the period of 2010-2011, a total of 56 HIV-infected patients and 57 healthy persons participated in this study. Among HIV positive patients, one person had positive test for HTILV-I/II representing the relative frequency of 1.8%, and in healthy individuals none of them were positive.
Conclusion: In our survey, relative frequency of HTLV-I/II was 1.8% in HIV+ patients. This study reveals that relative frequency of HTLV-I/II in HIV positive patients is considerable but determining the need for screening of HTLV-I/II requires further investigation.
Keywords
1. | Sertöz R, Turhan A, Bozkurt H, Samlýog lu P, Deg irmenci A, Aydýnok Y, et al. Investigation of anti-HTLV I/II seroprevalence in healthy blood donors in Izmir region, Turkey. Mikrobiyol Bul 2010;44:579-84. |
2. | Zucker-Franklin D, Pancake BA. Human T-cell lymphotropic virus type 1 tax among American blood donors. Clin Diagn Lab Immunol 1998;5:831-5. |
3. | Dias-Bastos MR, Oliveira CD, Carneiro-Proietti AB. Decline in prevalence and asymmetric distribution of human T cell lymphotropic virus 1 and 2 in blood donors, State of Minas Gerais, Brazil, 1993 to 2007. Rev Soc Bras Med Trop 2010;43:615-9. |
4. | Tulius Silva M, de Melo Espíndola O, Bezerra Leite AC, Araújo A. Neurological Aspects of HIV/Human T lymphotropic Virus Coinfection. AIDS Rev 2009;11:71-8. |
5. | Magri MC, Brigido LF, Rodrigues R, Morimoto HK, Ferreira JL, Caterino-de-Araujo A. Phylogenetic and similarity analysis of HTLV-1 Isolates from HIV-Coinfected patients from the South and Southeast regions of Brazil. AIDS Res Hum Retroviruses 2012;28:110-4. |
6. | Martín-Dávila P, Fortún J, López-Vélez R, Norman F, Montes de Oca M, Zamarrón P, et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008;21:60-96. |
7. | Madeleine MM, Wiktor SZ, Goedert JJ, Manns A, Levine PH, Biggar RJ, et al. HTLV-I and HTLV-II world-wide distribution: Reanalysis of 4,832 immunoblot results. Int J Cancer 1993;54:255-60. |
8. | Rafatpanah H, Farid R, Golanbar G, Jabbari Azad F. HTLV-I Infection: Virus structure, immune response to the virus and genetic association studies in HTLV-I-infected individuals. Iran J Allergy Asthma Immunol 2006;5:153-66. |
9. | Abbaszadegan MR, Gholamin M, Tabatabaee A, Farid R, Houshmand M, Abbaszadegan M. Prevalence of human T-lymphotropic virus type 1 among blood donors from Mashhad, Iran. J Clin Microbiol 2003;41:2593-5. |
10. | Barrientos A, Lopez M, Sotomayor C, Pilleux L, Calderón S, Navarrete M, et al. Prevalence of human T-cell lymphotropic virus type 1 and 2 among patients with malignant hematological diseases in south Chile. J Med Virol 2011;83:745-8. |
11. | Hedayati-Moghaddam MR, Fathimoghadam F, Eftekharzadeh Mashhadi I, Soghandi L, Bidkhori HR. Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran. Iran Red Crescent Med J 2011;13:424-7. |
12. | Caterino-de-Araujo A, Magri MC, Costa EA, Manuel RC. Prevalence of human T-cell lymphotropic virus (HTLV-1/2) in individuals from public health centers in Mozambique. AIDS Res Hum Retroviruses 2010;26:559-61. |
13. | Guimarães ML, Bastos FI, Telles PR, Galvão-Castro B, Diaz RS, Bongertz none V, et al. Retrovirus infections in a sample of injecting drug users in Rio de Janeiro City, Brazil: Prevalence of HIV-1 subtypes, and co-infection with HTLV-I/II. J Clin Virol 2001;21:143-51. |
14. | de los Angeles Pando M, Biglione MM, Toscano MF, Rey JA, Russell KL, Negrete M, et al. Human immunodeficiency virus type 1 and other viral co-infections among young heterosexual men and women in Argentina. Am J Trop Med Hyg 2004;71:153-9. |
15. | Meidani M, Farzaneh SH, Ajami A, Hasanzadeh A. Seroprevalence of HTLV1, 2 Virus Among Injection Drug Addicts in Isfahan. J Shaheed Sadoughi Univ Med Sci 2009;17:286-90. |
16. | Moayedi B, Nafisi A, Torabizade K. Contamination of HTLV1/2 In patients with thalassemia and its relation to blood levels of intake. Res Med Sci 1998;4:29-32. |